Home » USA Broker Ratings » DexCom, Inc. – Consenus Indicates Potential 1.2% Upside

DexCom, Inc. – Consenus Indicates Potential 1.2% Upside

DexCom, Inc. found using ticker (DXCM) have now 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 255 and 185 with the average target price sitting at 218.69. With the stocks previous close at 216.19 this would imply there is a potential upside of 1.2%. There is a 50 day moving average of 217.59 and the 200 day MA is 170.86. The company has a market capitalisation of $20,021m. Find out more information at: http://www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn